Autoantibodies against type 1 interferons linked to higher susceptibility to viral disease

FHS
July 18, 2024
11:16 pm

A new study shows that about two percent of the population develop autoantibodies against type 1 interferons, mostly later in life.

Paramagnetic Seeds: An Effective Option for Breast Lesion Localization

Paramagnetic seeds along with superparamagnetic iron oxide (SPIO) was an effective combination for nonpalpable breast lesion localization and sentinel lymph node detection (SLND), data from

January 3, 2024

Caresyntax Secures $180M to Advance Precision Surgery Platform

What You Should Know: – Caresyntax, a leader in vendor-neutral precision surgery platforms raises $180M in funding, comprised of $80M in equity and up to

August 17, 2024

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy – Pharmaceutical Technology

IGNYTE-3 tests the efficacy of RP1 against melanoma when other treatments have failed Replimune has announced the first patient in the Phase III melanoma trial

August 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.